The Novo Group
Novo Holdings is tasked with managing the assets and wealth of the Novo Nordisk Foundation. Our portfolio includes the controlling shares in the Novo Group companies, and an investment portfolio of life science and capital investments.
In 2022, the Novo Group Companies, Novo Nordisk A/S and Novozymes A/S, delivered historically strong results. Novo Nordisk’s sales increased by 26% in DKK and by 16% at constant exchange rates, and Novozymes reported 9% organic sales growth in 2022, marking the highest organic sales growth in more than a decade.
Novo Nordisk is a global healthcare company with more than 100 years of innovation and leadership in diabetes care. Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk A/S employs about 55,000 employees in 80 countries and markets its products in 168 countries. In 2022, Novo Nordisk A/S had revenue of USD 25.011 billion.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its American Depository Receipts (ADRs) are listed on the New York Stock Exchange (NVO).
Novozymes is the world leader in bioinnovation. Together with customers, partners and global society, the company improves industrial production and contributes to preserving natural resources and improving the quality of life. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food to advancing biofuels to power the world tomorrow.
Headquartered in Denmark, Novozymes A/S has more than 6,700 employees worldwide and markets more than 700 products in 140 countries. In 2022, Novozymes A/S had revenue of DKK 17.553 billion (EUR 2.3 billion).
Novozymes’ B shares are listed on NASDAQ OMX Copenhagen.
Novo Group and investments
Total Assets under Management (AuM) FY22 €108 billion – breakdown:
The Novo Group Charter
Present as well as future companies in the Novo Group must demonstrate willingness, ability and resolve to meet the following criteria:
company products and services make a significant difference in improving the way people live and work;
the company is perceived to be an innovator – in technology, in products, in services and/or in market approach;
the company is among the best in its business and a challenging place to work;
the company delivers competitive financial performance;
Companies in the Novo Group commit to:
open and honest dialogue with its stakeholders;
continuous improvement of financial performance, environmental performance and social performance;
reporting in accordance with relevant, internationally approved, conventions